| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00833eb7e281d7a79a641a04cbee57a1 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D225-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D245-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D243-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D223-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate |
2019-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a49ec20b6bebee803da7902279ee4d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cd07891c823f1ee660ddd666a706deb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03e63e2d10db7631d0b12226cef600d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc194ed3e36572b23795049096e60a73 |
| publicationDate |
2021-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021115002-A1 |
| titleOfInvention |
Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders |
| abstract |
AKR1C3-activated prodrugs of Formula (I), pharmaceutical compositions comprising prodrugs of Formula (I), and their use in the treatment of hyperproliferative diseases such as cancer and for cell ablation. The compounds of the invention are able to penetrate neoplasm tissue and be selectively reduced to an active (cytotoxic) form by contact with an AKR1C3 enzyme found in the neoplasm. This active form is therefore able to ablate AKR1C3-expressing target cells of the neoplasm and therefore has particular utility in the treatment of cancer and other hyperproliferative disorders. |
| priorityDate |
2018-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |